Ensuring 340B Discounts Trickle Down to Low-Income Patients
Congress must take action to ensure these discounts benefit low-income 340B eligible patients, as intended.

Congress must take action to ensure these discounts benefit low-income 340B eligible patients, as intended.
A recent advisory opinion released by HHS left many 340B advocates hungry for answers and pharmaceutical manufacturers frustrated.
A rise in suspect practices has been accompanied by a concomitant escalation of DOJ enforcement, sending a clear signal to would-be fraudulent actors.
The federal government recently used preemption unlawfully to prevent state public health efforts to protect vulnerable people from COVID-19.